A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome

DOI record: { "DOI": "10.1007/s43440-021-00296-2", "ISSN": [ "1734-1140", "2299-5684" ], "URL": "http://dx.doi.org/10.1007/s43440-021-00296-2", "alternative-id": [ "296" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "14 April 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Revised", "name": "revised", "order": 2, "value": "31 May 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 3, "value": "3 June 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 4, "value": "10 June 2021" }, { "group": { "label": "Declarations", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Conflict of interest", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "The authors declare that they have no competing interests." }, { "group": { "label": "Ethical approval and consent to participate", "name": "EthicsHeading" }, "name": "Ethics", "order": 3, "value": "The trial protocol was according to the Declaration of Helsinki as revised in 1989, and the study protocol was approved by the research and ethics committee at Hamadan University of Medical Sciences (IR.UMSHA.REC.13999.153)." }, { "group": { "label": "Consent for publication", "name": "EthicsHeading" }, "name": "Ethics", "order": 4, "value": "All authors have given consent for publication." }, { "label": "Free to read", "name": "free", "value": "This content has been made available to all." } ], "author": [ { "affiliation": [], "family": "Taher", "given": "Abbas", "sequence": "first" }, { "affiliation": [], "family": "Lashgari", "given": "Marjan", "sequence": "additional" }, { "affiliation": [], "family": "Sedighi", "given": "Ladan", "sequence": "additional" }, { "affiliation": [], "family": "Rahimi-bashar", "given": "Farshid", "sequence": "additional" }, { "affiliation": [], "family": "Poorolajal", "given": "Jalal", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-4119-1600", "affiliation": [], "authenticated-orcid": false, "family": "Mehrpooya", "given": "Maryam", "sequence": "additional" } ], "clinical-trial-number": [ { "clinical-trial-number": "irct20120215009014n355", "registry": "10.18810/irct" } ], "container-title": [ "Pharmacological Reports" ], "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2021, 6, 10 ] ], "date-time": "2021-06-10T18:02:48Z", "timestamp": 1623348168000 }, "deposited": { "date-parts": [ [ 2021, 11, 18 ] ], "date-time": "2021-11-18T05:15:49Z", "timestamp": 1637212549000 }, "indexed": { "date-parts": [ [ 2021, 12, 13 ] ], "date-time": "2021-12-13T13:18:15Z", "timestamp": 1639401495833 }, "is-referenced-by-count": 2, "issn-type": [ { "type": "print", "value": "1734-1140" }, { "type": "electronic", "value": "2299-5684" } ], "issue": "6", "issued": { "date-parts": [ [ 2021, 6, 10 ] ] }, "journal-issue": { "issue": "6", "published-print": { "date-parts": [ [ 2021, 12 ] ] } }, "language": "en", "license": [ { "URL": "https://www.springer.com/tdm", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 6, 10 ] ], "date-time": "2021-06-10T00:00:00Z", "timestamp": 1623283200000 } }, { "URL": "https://www.springer.com/tdm", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 6, 10 ] ], "date-time": "2021-06-10T00:00:00Z", "timestamp": 1623283200000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1007/s43440-021-00296-2.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1007/s43440-021-00296-2/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1007/s43440-021-00296-2.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "page": "1650-1659", "prefix": "10.1007", "published": { "date-parts": [ [ 2021, 6, 10 ] ] }, "published-online": { "date-parts": [ [ 2021, 6, 10 ] ] }, "published-print": { "date-parts": [ [ 2021, 12 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "author": "WHO", "key": "296_CR1", "unstructured": "WHO. WHO director-general’s remarks at the media briefing on 2019-nCoV on 11 February 2020. WHO; 2020.", "volume-title": "WHO director-general’s remarks at the media briefing on 2019-nCoV on 11 February 2020", "year": "2020" }, { "author": "CPERE Novel", "first-page": "145", "journal-title": "Zhonghua Liu Xing Bing Xue Za Zhi", "key": "296_CR2", "unstructured": "CPERE Novel. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41:145.", "volume": "41", "year": "2020" }, { "DOI": "10.1016/S2213-2600(20)30079-5", "author": "X Yang", "doi-asserted-by": "crossref", "first-page": "475", "journal-title": "Lancet Respir Med", "key": "296_CR3", "unstructured": "Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475–81.", "volume": "8", "year": "2020" }, { "author": "ADT Force", "first-page": "2526", "journal-title": "JAMA", "key": "296_CR4", "unstructured": "Force ADT, Ranieri V, Rubenfeld G, Thompson B, Ferguson N, Caldwell E. Acute respiratory distress syndrome. JAMA. 2012;307:2526–33.", "volume": "307", "year": "2012" }, { "DOI": "10.1016/j.tmaid.2020.101623", "author": "AJ Rodriguez-Morales", "doi-asserted-by": "crossref", "first-page": "101623", "journal-title": "Travel Med Infect Dis", "key": "296_CR5", "unstructured": "Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623.", "volume": "34", "year": "2020" }, { "DOI": "10.1515/hsz-2013-0241", "author": "J Lugrin", "doi-asserted-by": "crossref", "first-page": "203", "journal-title": "Biol Chem", "key": "296_CR6", "unstructured": "Lugrin J, Rosenblatt-Velin N, Parapanov R, Liaudet L. The role of oxidative stress during inflammatory processes. Biol Chem. 2014;395:203–30.", "volume": "395", "year": "2014" }, { "DOI": "10.1016/j.niox.2020.06.002", "author": "J Wu", "doi-asserted-by": "publisher", "first-page": "39", "journal-title": "Nitric Oxide", "key": "296_CR7", "unstructured": "Wu J. Tackle the free radicals damage in COVID-19. Nitric Oxide. 2020;102:39–41. https://doi.org/10.1016/j.niox.2020.06.002. Accessed 17 June 2020.", "volume": "102", "year": "2020" }, { "DOI": "10.1016/j.ijantimicag.2020.105954", "author": "C Zhang", "doi-asserted-by": "crossref", "first-page": "105954", "journal-title": "Int J Antimicrob Agents", "key": "296_CR8", "unstructured": "Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55:105954.", "volume": "55", "year": "2020" }, { "DOI": "10.1007/s12250-020-00207-4", "author": "Y Fu", "doi-asserted-by": "crossref", "first-page": "266", "journal-title": "Virol Sin", "key": "296_CR9", "unstructured": "Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin. 2020;35:266–71.", "volume": "35", "year": "2020" }, { "DOI": "10.1016/j.jinf.2020.03.037", "author": "Q Ye", "doi-asserted-by": "crossref", "first-page": "607", "journal-title": "J Infect", "key": "296_CR10", "unstructured": "Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020;80:607–13.", "volume": "80", "year": "2020" }, { "DOI": "10.1093/cid/ciab055", "doi-asserted-by": "publisher", "key": "296_CR11", "unstructured": "Lapenna D Antioxidant therapy in COVID-19: the crucial role of early treatment and antioxidant typology. Clin Infect Dis. 2021. https://doi.org/10.1093/cid/ciab055." }, { "author": "WHO", "key": "296_CR12", "unstructured": "WHO. Corticosteroids for COVID-19: living guidance, 2 September 2020. World Health Organization; 2020.", "volume-title": "Corticosteroids for COVID-19: living guidance, 2 September 2020", "year": "2020" }, { "DOI": "10.1007/s000180300001", "author": "M Zafarullah", "doi-asserted-by": "crossref", "first-page": "6", "journal-title": "Cell Mol Life Sci", "key": "296_CR13", "unstructured": "Zafarullah M, Li W, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci. 2003;60:6–20.", "volume": "60", "year": "2003" }, { "author": "PJ Millea", "first-page": "265", "journal-title": "Am Fam Physician", "key": "296_CR14", "unstructured": "Millea PJ. N-acetylcysteine: multiple clinical applications. Am Fam Physician. 2009;80:265–9.", "volume": "80", "year": "2009" }, { "author": "E Dass", "first-page": "69", "issue": "3–", "journal-title": "J Biomed Pharm Res", "key": "296_CR15", "unstructured": "Dass E. Brief review of N-acetylcysteine as antiviral agent: potential application in COVID-19. J Biomed Pharm Res. 2020;9(3):69–73.", "volume": "9", "year": "2020" }, { "DOI": "10.1183/09031936.97.10071535", "author": "S De Flora", "doi-asserted-by": "crossref", "first-page": "1535", "journal-title": "Eur Respir J", "key": "296_CR16", "unstructured": "De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J. 1997;10:1535–41.", "volume": "10", "year": "1997" }, { "DOI": "10.1016/j.bcp.2011.05.014", "author": "M Mata", "doi-asserted-by": "crossref", "first-page": "548", "journal-title": "Biochem Pharmacol", "key": "296_CR17", "unstructured": "Mata M, Morcillo E, Gimeno C, Cortijo J. N-acetyl-l-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Biochem Pharmacol. 2011;82:548–55.", "volume": "82", "year": "2011" }, { "DOI": "10.1378/chest.112.1.164", "author": "GR Bernard", "doi-asserted-by": "crossref", "first-page": "164", "journal-title": "Chest", "key": "296_CR18", "unstructured": "Bernard GR, Wheeler AP, Arons MM, Morris PE, Paz HL, Russell JA, et al. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. Chest. 1997;112:164–72.", "volume": "112", "year": "1997" }, { "DOI": "10.1177/0960327107083452", "author": "MS Soltan-Sharifi", "doi-asserted-by": "crossref", "first-page": "697", "journal-title": "Hum Exp Toxicol", "key": "296_CR19", "unstructured": "Soltan-Sharifi MS, Mojtahedzadeh M, Najafi A, Khajavi MR, Rouini MR, Moradi M, et al. Improvement by N-acetylcysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and anti-oxidant power: evidence for underlying toxicological mechanisms. Hum Exp Toxicol. 2007;26:697–703.", "volume": "26", "year": "2007" }, { "author": "R Mohanty", "first-page": "2802", "journal-title": "Eur Rev Med Pharmacol Sci", "key": "296_CR20", "unstructured": "Mohanty R, Padhy B, Das S, Meher B. Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence. Eur Rev Med Pharmacol Sci. 2021;25:2802–7.", "volume": "25", "year": "2021" }, { "author": "C Puyo", "first-page": "491", "journal-title": "F1000Research", "key": "296_CR21", "unstructured": "Puyo C, Kreig D, Saddi V, Ansari E, Prince O. Case report: Use of hydroxychloroquine and N-acetylcysteine for treatment of a COVID-19 positive patient. F1000Research. 2020;9:491.", "volume": "9", "year": "2020" }, { "DOI": "10.1097/MD.0000000000022577", "author": "Y Liu", "doi-asserted-by": "publisher", "first-page": "e22577", "issue": "42", "journal-title": "Medicine", "key": "296_CR22", "unstructured": "Liu Y, Wang M, Luo G, Qian X, Wu C, Zhang Y, et al. Experience of N-acetylcysteine airway management in the successful treatment of one case of critical condition with COVID-19: a case report. Medicine. 2020;99(42):e22577. https://doi.org/10.1097/MD.0000000000022577.", "volume": "99", "year": "2020" }, { "DOI": "10.1016/j.toxrep.2020.06.003", "author": "A Nasi", "doi-asserted-by": "crossref", "first-page": "768", "journal-title": "Toxicol Rep", "key": "296_CR23", "unstructured": "Nasi A, McArdle S, Gaudernack G, Westman G, Melief C, Rockberg J, et al. Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention. Toxicol Rep. 2020;7:768–71.", "volume": "7", "year": "2020" }, { "DOI": "10.1016/j.clim.2020.108544", "author": "H Ibrahim", "doi-asserted-by": "crossref", "first-page": "108544", "journal-title": "Clin Immunol", "key": "296_CR24", "unstructured": "Ibrahim H, Perl A, Smith D, Lewis T, Kon Z, Goldenberg R, et al. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. Clin Immunol. 2020;219:108544.", "volume": "219", "year": "2020" }, { "DOI": "10.1378/chest.105.1.190", "author": "PM Suter", "doi-asserted-by": "crossref", "first-page": "190", "journal-title": "Chest", "key": "296_CR25", "unstructured": "Suter PM, Domenighetti G, Schaller M-D, Laverrière M-C, Ritz R, Perret C. N-acetylcysteine enhances recovery from acute lung injury in man: a randomized, double-blind, placebo-controlled clinical study. Chest. 1994;105:190–4.", "volume": "105", "year": "1994" }, { "author": "DM Radomska-Leśniewska", "first-page": "57", "journal-title": "Cent Eur J Immunol", "key": "296_CR26", "unstructured": "Radomska-Leśniewska DM, Skopiński P. Review paper N-acetylcysteine as an anti-oxidant and anti-inflammatory drug and its some clinical applications. Cent Eur J Immunol. 2012;37:57–66.", "volume": "37", "year": "2012" }, { "DOI": "10.1177/0885066617696850", "author": "J Chertoff", "doi-asserted-by": "crossref", "first-page": "87", "journal-title": "J Intensive Care Med", "key": "296_CR27", "unstructured": "Chertoff J. N-acetylcysteine’s role in sepsis and potential benefit in patients with microcirculatory derangements. J Intensive Care Med. 2018;33:87–96.", "volume": "33", "year": "2018" }, { "DOI": "10.1371/journal.ppat.1006286", "author": "M Poppe", "doi-asserted-by": "crossref", "first-page": "e1006286", "journal-title": "PLoS Pathog", "key": "296_CR28", "unstructured": "Poppe M, Wittig S, Jurida L, Bartkuhn M, Wilhelm J, Müller H, et al. The NF-κB-dependent and-independent transcriptome and chromatin landscapes of human coronavirus 229E-infected cells. PLoS Pathog. 2017;13:e1006286.", "volume": "13", "year": "2017" }, { "DOI": "10.1177/039463200401700114", "author": "P Ghezzi", "doi-asserted-by": "crossref", "first-page": "99", "journal-title": "Int J Immunopathol Pharmacol", "key": "296_CR29", "unstructured": "Ghezzi P, Ungheri D. Synergistic combination of N-acetylcysteine and ribavirin to protect from lethal influenza viral infection in a mouse model. Int J Immunopathol Pharmacol. 2004;17:99–102.", "volume": "17", "year": "2004" }, { "DOI": "10.1371/journal.pone.0048037", "author": "M Mata", "doi-asserted-by": "crossref", "first-page": "e48037", "journal-title": "PLoS ONE", "key": "296_CR30", "unstructured": "Mata M, Sarrion I, Armengot M, Carda C, Martinez I, Melero JA, et al. Respiratory syncytial virus inhibits ciliagenesis in differentiated normal human bronchial epithelial cells: effectiveness of N-acetylcysteine. PLoS ONE. 2012;7:e48037.", "volume": "7", "year": "2012" }, { "DOI": "10.1016/j.bcp.2009.08.025", "author": "J Geiler", "doi-asserted-by": "crossref", "first-page": "413", "journal-title": "Biochem Pharmacol", "key": "296_CR31", "unstructured": "Geiler J, Michaelis M, Naczk P, Leutz A, Langer K, Doerr H-W, et al. N-acetyl-l-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol. 2010;79:413–20.", "volume": "79", "year": "2010" }, { "DOI": "10.1093/cid/ciaa248", "author": "C Qin", "doi-asserted-by": "crossref", "first-page": "762", "journal-title": "Clin Infect Dis", "key": "296_CR32", "unstructured": "Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71:762–8.", "volume": "71", "year": "2020" }, { "DOI": "10.1096/fj.202001807", "author": "S De Flora", "doi-asserted-by": "crossref", "first-page": "13185", "journal-title": "FASEB J", "key": "296_CR33", "unstructured": "De Flora S, Balansky R, La Maestra S. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. FASEB J. 2020;34:13185–93.", "volume": "34", "year": "2020" }, { "DOI": "10.1016/j.mehy.2020.110133", "author": "N Jaiswal", "doi-asserted-by": "crossref", "first-page": "110133", "journal-title": "Med Hypotheses", "key": "296_CR34", "unstructured": "Jaiswal N, Bhatnagar M, Shah H. N-acetylcysteine: a potential therapeutic agent in COVID-19 infection. Med Hypotheses. 2020;144:110133.", "volume": "144", "year": "2020" }, { "key": "296_CR35", "unstructured": "Van Hecke O, Lee J. N-acetylcysteine: a rapid review of the evidence for effectiveness in treating COVID-19. 2020. https://hdl.handle.net/20.500.12663/1089." }, { "DOI": "10.1016/S0140-6736(20)30183-5", "author": "C Huang", "doi-asserted-by": "crossref", "first-page": "497", "journal-title": "Lancet", "key": "296_CR36", "unstructured": "Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.", "volume": "395", "year": "2020" }, { "DOI": "10.1016/S0140-6736(03)13413-7", "author": "JM Nicholls", "doi-asserted-by": "crossref", "first-page": "1773", "journal-title": "Lancet", "key": "296_CR37", "unstructured": "Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003;361:1773–8.", "volume": "361", "year": "2003" }, { "DOI": "10.2147/TCRM.S273700", "author": "Z Shi", "doi-asserted-by": "crossref", "first-page": "1047", "journal-title": "Ther Clin Risk Manag", "key": "296_CR38", "unstructured": "Shi Z, Puyo CA. N-acetylcysteine to combat COVID-19: an evidence review. Ther Clin Risk Manag. 2020;16:1047.", "volume": "16", "year": "2020" }, { "DOI": "10.1016/j.rmed.2008.09.013", "author": "M Moradi", "doi-asserted-by": "crossref", "first-page": "434", "journal-title": "Respir Med", "key": "296_CR39", "unstructured": "Moradi M, Mojtahedzadeh M, Mandegari A, Soltan-Sharifi MS, Najafi A, Khajavi MR, et al. The role of glutathione-S-transferase polymorphisms on clinical outcome of ALI/ARDS patient treated with N-acetylcysteine. Respir Med. 2009;103:434–41.", "volume": "103", "year": "2009" }, { "DOI": "10.1097/00024382-200013010-00003", "author": "O Ortolani", "doi-asserted-by": "crossref", "first-page": "14", "journal-title": "Shock", "key": "296_CR40", "unstructured": "Ortolani O, Conti A, De Gaudio AR, Masoni M, Novelli G. Protective effects of N-acetylcysteine and rutin on the lipid peroxidation of the lung epithelium during the adult respiratory distress syndrome. Shock. 2000;13:14–8.", "volume": "13", "year": "2000" }, { "DOI": "10.1016/S0883-9441(97)90029-0", "author": "G Domenighetti", "doi-asserted-by": "crossref", "first-page": "177", "journal-title": "J Crit Care", "key": "296_CR41", "unstructured": "Domenighetti G, Suter PM, Schaller M-D, Ritz R, Perret C. Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study. J Crit Care. 1997;12:177–82.", "volume": "12", "year": "1997" }, { "DOI": "10.1097/00003246-199207000-00004", "author": "S Jepsen", "doi-asserted-by": "crossref", "first-page": "918", "journal-title": "Crit Care Med", "key": "296_CR42", "unstructured": "Jepsen S, Herlevsen P, Knudsen P, Bud MI, Klausen N. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: a prospective, randomized, placebo-controlled study. Crit Care Med. 1992;20:918–23.", "volume": "20", "year": "1992" }, { "DOI": "10.3892/etm.2017.4891", "author": "Y Zhang", "doi-asserted-by": "crossref", "first-page": "2863", "journal-title": "Exp Ther Med", "key": "296_CR43", "unstructured": "Zhang Y, Ding S, Li C, Wang Y, Chen Z, Wang Z. Effects of N-acetylcysteine treatment in acute respiratory distress syndrome: a meta-analysis. Exp Ther Med. 2017;14:2863–8.", "volume": "14", "year": "2017" }, { "DOI": "10.1016/j.ejphar.2020.173494", "author": "DH Alamdari", "doi-asserted-by": "crossref", "first-page": "173494", "journal-title": "Eur J Pharmacol", "key": "296_CR44", "unstructured": "Alamdari DH, Moghaddam AB, Amini S, Keramati MR, Zarmehri AM, Alamdari AH, et al. Application of methylene blue-vitamin C–N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial. Eur J Pharmacol. 2020;885:173494.", "volume": "885", "year": "2020" }, { "DOI": "10.3389/fimmu.2020.01441", "author": "LF García", "doi-asserted-by": "crossref", "first-page": "1441", "journal-title": "Front Immunol", "key": "296_CR45", "unstructured": "García LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol. 2020;11:1441.", "volume": "11", "year": "2020" }, { "DOI": "10.3390/jcm9124021", "author": "V Lariccia", "doi-asserted-by": "crossref", "first-page": "4021", "journal-title": "J Clin Med", "key": "296_CR46", "unstructured": "Lariccia V, Magi S, Serfilippi T, Toujani M, Gratteri S, Amoroso S. Challenges and opportunities from targeting inflammatory responses to SARS-CoV-2 infection: a narrative review. J Clin Med. 2020;9:4021.", "volume": "9", "year": "2020" }, { "DOI": "10.1016/S0735-1097(02)01797-7", "author": "J Sochman", "doi-asserted-by": "crossref", "first-page": "1422", "journal-title": "J Am Coll Cardiol", "key": "296_CR47", "unstructured": "Sochman J. N-acetylcysteine in acute cardiology: 10 years later: what do we know and what would we like to know?! J Am Coll Cardiol. 2002;39:1422–8.", "volume": "39", "year": "2002" }, { "DOI": "10.2147/NDT.S241497", "author": "M Sabetghadam", "doi-asserted-by": "crossref", "first-page": "1265", "journal-title": "Neuropsychiatr Dis Treat", "key": "296_CR48", "unstructured": "Sabetghadam M, Mazdeh M, Abolfathi P, Mohammadi Y, Mehrpooya M. Evidence for a beneficial effect of oral N-acetylcysteine on functional outcomes and inflammatory biomarkers in patients with acute ischemic stroke. Neuropsychiatr Dis Treat. 2020;16:1265.", "volume": "16", "year": "2020" }, { "DOI": "10.3390/ijms21186790", "author": "A Samidurai", "doi-asserted-by": "crossref", "first-page": "6790", "journal-title": "Int J Mol Sci", "key": "296_CR49", "unstructured": "Samidurai A, Das A. Cardiovascular complications associated with COVID-19 and potential therapeutic ~ strategies. Int J Mol Sci. 2020;21:6790.", "volume": "21", "year": "2020" }, { "DOI": "10.1016/j.jocn.2020.05.017", "author": "I Ahmad", "doi-asserted-by": "publisher", "first-page": "8", "journal-title": "J Clin Neurosci", "key": "296_CR50", "unstructured": "Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: a literature review. J Clin Neurosci. 2020;77:8–12. https://doi.org/10.1016/j.jocn.2020.05.017. Accessed 6 May 2020.", "volume": "77", "year": "2020" }, { "DOI": "10.1177/102490790701400402", "doi-asserted-by": "crossref", "key": "296_CR51", "unstructured": "Meri W, Koutsogiannis Z, Kerr D, Kelly. How safe is intravenous N-Acetylcysteine for the treatment of paracetamol\npoisoning?. Hong Kong J Emerg Med 2007, 14(4):198–203." }, { "DOI": "10.1016/j.phrs.2005.11.003", "author": "AM Sadowska", "doi-asserted-by": "crossref", "first-page": "216", "journal-title": "Pharmacol Res", "key": "296_CR52", "unstructured": "Sadowska AM, Manuel-y-Keenoy B, Vertongen T, Schippers G, Radomska-Lesniewska D, Heytens E, et al. Effect of N-acetylcysteine on neutrophil activation markers in healthy volunteers: in vivo and in vitro study. Pharmacol Res. 2006;53:216–25.", "volume": "53", "year": "2006" }, { "DOI": "10.2165/00003088-199120020-00004", "author": "MR Holdiness", "doi-asserted-by": "crossref", "first-page": "123", "journal-title": "Clin Pharmacokinet", "key": "296_CR53", "unstructured": "Holdiness MR. Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet. 1991;20:123–34.", "volume": "20", "year": "1991" }, { "DOI": "10.1007/s11999-010-1287-7", "author": "SR Kearns", "doi-asserted-by": "crossref", "first-page": "2251", "journal-title": "Clin Orthop Relat Res", "key": "296_CR54", "unstructured": "Kearns SR, O’Briain DE, Sheehan KM, Kelly C, Bouchier-Hayes D. N-acetylcysteine protects striated muscle in a model of compartment syndrome. Clin Orthop Relat Res. 2010;468:2251–9.", "volume": "468", "year": "2010" } ], "reference-count": 54, "references-count": 54, "relation": {}, "score": 1, "short-container-title": [ "Pharmacol. Rep" ], "short-title": [], "source": "Crossref", "subject": [ "Pharmacology", "General Medicine" ], "subtitle": [], "title": [ "A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome" ], "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "volume": "73" }